Abstract
As we begin to recover from the COVID-19 pandemic, a key question is if we can avert such disasters in future. Current surveillance protocols generally focus on qualitative impact assessments of viral diversity 1. These efforts are primarliy aimed at ecosystem and human impact monitoring, and do not help to precisely quantify emergence. Currently, the similarity of biological strains is measured by the edit distance or the number of mutations that separate their genomic sequences 2–6, e.g. the number of mutations that make an avian flu strain human-adapted. However, ignoring the odds of those mutations in the wild keeps us blind to the true jump risk, and gives us little indication of which strains are more risky. In this study, we develop a more meaningful metric for comparison of genomic sequences. Our metric, the q-distance, precisely quantifies the probability of spontaneous jump by random chance. Learning from patterns of mutations from large sequence databases, the q-distance adapts to the specific organism, the background population, and realistic selection pressures; demonstrably improving inference of ancestral relationships and future trajectories. As important application, we show that the q-distance predicts future strains for seasonal Influenza, outperforming World Health Organization (WHO) recommended flu-shot composition almost consistently over two decades. Such performance is demonstrated separately for Northern and Southern hemisphere for different subtypes, and key capsidic proteins. Additionally, we investigate the SARS-CoV-2 origin problem, and precisely quantify the likelihood of different animal species that hosted an immediate progenitor, producing a list of related species of bats that have a quantifiably high likelihood of being the source. Additionally, we identify specific rodents with a credible likelihood of hosting a SARS-CoV-2 ancestor. Combining machine learning and large deviation theory, the analysis reported here may open the door to actionable predictions of future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is funded in part by the Defense Advanced Research Projects Agency (DARPA) project #FP070943-01-PR. The claims made in this study do not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No Human Patient Data
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Models generated in this study is included as supplementary material, and working software is publicly available at https://pypi.org/project/quasinet/. Accession numbers of all sequences used, and acknowledgement documentation for GISAID sequences in also available as supplementary information.
https://github.com/zeroknowledgediscovery/quasinet/tree/master/examples
